Aerocrine acquires FENO assets from FILT and enters into R&D collaboration
SOLNA, Sweden – 18 March 2011 – Aerocrine AB today announced the acquisition of key assets related to the measurement of FENO from German company FILT Lungen & Thoraxdiagnostik GmbH. FILT and Aerocrine will collaborate to develop new applications for airway inflammation monitoring and FILT will cease further commercialization of the NO VARIO® product.
Over many years, Aerocrine has made very significant technological, clinical and commercial investments to develop the market for its inventions to measure airway inflammation in asthma and other respiratory disorders. Today, Aerocrine is the only company supplying quality-assured products for FENO monitoring approved by major regulatory authorities, including the FDA and SFDA, across the world. The company continues to invest in clinical trials and technology development for the benefit of care providers and people living with asthma.
“The technology platform and intellectual property acquired from FILT may prove valuable for our continued endeavors to further develop innovative products to measure airway inflammation”, says Paul de Potocki, CEO of Aerocrine. “We look forward to working together with FILT and its General Manager, Mr. Rüdiger Eichler, who brings considerable technical expertise in the field.”
“It requires significant resources to develop the technology and the international clinical documentation for products used in a major therapeutic area such as asthma. Aerocrine is the market leader and the ideal partner for FILT related to airway inflammation monitoring,” says Mr. Eichler.
Following the consummation of the agreements, Aerocrine will cause appropriate papers to be filed in the Regional Court of Düsseldorf to withdraw its pending claims of patent infringement against FILT.
For more information, contact:
Paul de Potocki, CEO, telephone: +46 8 629 07 80
Mats Carlson, VP Technical Operations & Development, telephone: +46 8 629 0783
About Aerocrine Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 13:00 p.m. on March the 18th 2011.